PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide,an androgen receptor antagonist,in prolonging metastasisfree survival in men with nonmetastatic castration-resistant prosta...
ACKNOWLEDGMENTS This study was supported by the National Natural Science Foundation of China (Grants 81472683 and 81202275), Tianjin Natural Science fund (Grant 13JCQNJC 11000) and Research Seed Foundation of Tianjin Medical University Gancer Hospital and Institute (Grant 1421).
Compared with female breast cancer, male breast cancer is a rare disease, and the relationship between clinical/pathologic features and prognosis is controversial, or even largely unknown. In this study, we performed ...